![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
healthy_back Содержание https://healthy-back.dreamwidth.org/412990.html
1. Guilleminault C and De Los Reyes V [2011] Upper‐airway resistance syndrome. Handbook of Clinical Neurology 98: 401‐409.
2. Newman JP, Clerk AA, Moore M, Utley DS and Terris DJ [1996] Recognition and surgical management of the upper airway resistance syndrome. Laryngoscope 106 (9 Pt 1): 1089‐1093.
3. Lin CH and Guilleminault C [2011] Current hypopnea scoring criteria underscore pediatric sleep disordered breathing. Sleep Medicine 12: 720‐729.
4. Ruehland WR, Rochford PD, O’Donoghue FJ, Pierce RJ, Singh P and Thornton AT [2009] The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index. Sleep 32: 150‐157.
5. Gold AR, Dipalo F, Gold MS and O’Hearn D [2003] The symptoms and signs of upper airway resistance syndrome: a link to the functional somatic syndromes. Chest 123: 87‐95.
6. Guilleminault C, Kirisoglu C, Poyares D, Palombini L, Leger D, Farid‐Moayer M and Ohayon MM [2006] Upper Airway Resistance Syndrome: a long‐term outcome study. J Psychiatr Res 40: 273‐279.
7. Park SY [2008] Sleep Interrupted. New York: Jodev Press, LLC.
8. Haba‐Rubio J, Andries D, Bastardot F, Tobback N, Vollenweider P, Tafti M and Heinzer R [2011] Prevalence of sleep disordered breathing in middle‐aged general population: the Hypnolaus study. Sleep 34: A123
9. Tufik S, Santos‐Silva R, Taddei JA and Azeredo Bittencourt LR [2010] Obstructive sleep apnea syndrome in the Sao Paolo epidemiologic sleep study. Sleep Medicine 11: 441‐446.
10. Umlauf MG and Chasens ER [2003] Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med Rev 7: 403‐411.
11. Kalra PR and Tigas S [2002] Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125‐132.
12. Potter LF, Yoder AR, Flora DR, Antos LK and Dickey DM [2009] Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191: 341‐366.
13. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA and Livesey JH [1986] Metabolic clearance rate and plasma half life of alpha‐human atrial natriuretic peptide in man. Life Sci 38: 1827‐1833.
14. Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H, Uemura S and Saito Y [2007] ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 63: 699‐702.
15. Ikeda N, Yasu T, Nishikimi T, Nakamura T, Kubo N, Kawakami M, Momomura S and Saito M [2007] N‐terminal pro‐atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. Regul Pept 141(1‐3): 154‐158.
16. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T and Burnett JC Jr [2010] A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension 56: 1152‐1159.
17. Imaizumi T and Takeshita A [1993] Influence of ANP on sympathetic nerve activity and chronotropic regulation of the heart. J Cardiovasc Electrophysiol 4: 719‐729.
18. Porzionato A, Macchi V, Rucinski M, Malendowicz LK and De Caro R [2010] Natriuretic peptides in the regulation of the hypothalamic‐pituitary‐adrenal axis. Int Rev Cell Mol Biol 280: 1‐39.
19. Chartier L, Schiffrin E and Thibault G [1984] Effect of atrial natriuretic factor (ANF)‐related peptides on aldosterone secretion by adrenal glomerulosa cells: critical role of the intramolecular disulphide bond. Biochem Biophys Res Commun 122: 171‐174.
20. Atlas SA, Volpe M, Sosa RE, Laragh JH, Camargo MJ and Maack T [1986] Effects of atrial natriuretic factor on blood pressure and the renin‐angiotensin‐aldosterone system. Fed Proc 45: 2115‐2121.
21. Pizzorno JE and Murray MT [1999] Textbook of Natural Medicine, second edition. Edinburgh: Harcourt Publishers Limited.
22. Demitrack MA, Dale JK and Straus SE [1991] Evidence for impaired activation of the hypothalamic‐pituitary‐adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 73: 1224‐1234.
23. Demiralay C, Jahn H, Kellner M, Yassouridis A and Weidemann K [2010] Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic‐pituitary‐adrenal axis and sleep in healthy men. Psychoneuroendocrinology 35: 1438‐1445.
24. Perras B, Schultes B, Behn B, Dodt C, Born J and Fehm HL [2004] Intranasal atrial natriuretic peptide acts as central nervous inhibitor of the hypothalamic‐pituitary‐adrenal stress system in humans. J Clin Endocrinol Metab 89: 4642‐4648.
25. Boneva RS, Decker MJ, Maloney EM, Lin JM, Jones JF, Helgason HG, Heim CM, Rye DB and Reeves WC [2007] Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population based study. Auton Neurosci 137: 94‐101.
26. Anderberg UM and Uvnas‐Moberg K [2000] Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 59: 373‐379.
27. Wyller VB, Evang JA, Godang K, Solhjell KK and Bollerslev J [2010] Hormonal alterations in adolescent chronic fatigue syndrome. Acta Paediatr 99: 770‐773.
28. Krakow B, Melendrez D, Warner TD, Dorin R, Harper R and Hollifield M [2002] To breathe, perchance to sleep: sleep‐disordered breathing and chronic insomnia among trauma survivors. Sleep Breath 6: 189‐202.
29. Gold AR [2011] Functional somatic syndromes, anxiety disorders and the upper airway: A matter of paradigms. Sleep Med Rev 15: 389‐401.
30. Amin MM, Belisova Z, Hossain S, Gold MS, Broderick JE and Gold AR [2011] Inspiratory airflow dynamics during sleep in veterans with Gulf War illness: a controlled study. Sleep Breath 15: 333‐339.
31. Freund BJ, Wade CE and Claybaugh J [1988] Effects of exercise on atrial natriuretic factor. Release mechanisms and implications for fluid homeostasis. Sports Med 6: 364‐377.
32. Kita H, Ohi M, Chin K, Noguchi T, Otsuka N, Tsuboi T, Itoh H, Nakao K and Kuno K [1998] The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 7: 199‐207.
33. Schafer H, Ehlenz K, Ewig S, Hasper E, Koehler U, Latzelsberger J, Tasci S and Luderitz B [1999] Atrial natriuretic peptide levels and pulmonary artery pressure awake, at exercise and asleep in obstructive sleep apnoea syndrome. J Sleep Res 8: 205‐210.
34. Svatikova A, Shamsuzzaman, AS, Wolk R, Phillips BG, Olson LJ and Somers VK [2004] Plasma brain natriuretic peptide in obstructive sleep apnea. Am J Cardiol 94: 529‐532.
35. Lin CC, Tsan KW and Lin CY [1993] Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep 16: 37‐39.
36. Ichioka M, Hirata Y, Inase N, Tojo N, Yoshizawa M, Chida M, Miyazato I, Taniai S and Marumo F [1992] Changes of circulating atrial natriuretic peptide and antidiuretic hormone in obstructive sleep apnea syndrome. Respiration 59: 164‐168.
37. Patwardhan AA, Larson MG, Levy D, Benjamin EF, Leip EP, Keyes MJ, Wang TJ, Gottlieb DJ and Vasan RS [2006] Obstructive sleep apnea and plasma natriuretic peptide levels in a community‐based sample. Sleep 29: 1301‐1306.
38. Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V and Poulin MJ [2010] Intermittent hypoxia increases arterial blood pressure in humans through a Renin‐Angiotensin system‐dependent mechanism. Hypertension 56: 369‐377.
39. Møller DS, Lind P, Strunge B and Pedersen EB [2003] Abnormal vasoactive hormones and 24‐hour blood pressure in obstructive sleep apnea. Am J Hypertens 16: 274‐280.
40. Matsukawa T and Miyamoto T [2011] Angiotensin II‐stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol 300: R624‐R629.
41. Oh YB, Gao S, Shah A, Kim JH, Park WH and Kim SH [2011] Endogenous angiotensin II suppresses stretch‐induced ANP secretion via AT1 receptor pathway. Peptides 32: 374‐381.
42. Dietz JR [2005] Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 66: 8‐17.
43. De Pergola G, Garruti G, Giorgino F, Cospite MR, Corso M, Cignarelli M and Giorgino R [1994] Reduced effectiveness of atrial natriuretic factor in pre‐menopausal obese women. Int J Obes Relat Metab Disord 18: 93‐97.
44. Beltowski J, Jamroz‐Wisniewka A, Borkowska E and Marciniak A [2006] Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic peptide associated with obesity and hyperleptinemia 37: 307‐315.
45. Schiffrin EL and St‐Louis J [1987] Decreased density of vascular receptors for atrial natriuretic peptide in DOCA‐salt hypertensive rats. Hypertension 9: 504‐512.
46. Licata G, Volpe M, Scaglione R and Rubattu S [1994] Salt‐regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23(1 Suppl): 120‐124.
47. Rubattu, S, Sciarretta S, Ciavarella GM, Venturelli V, De Paolis P, Tocci G, De Biase L, Ferrucci A and Volpe M [2007] Reduced levels of N‐terminal‐proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertens 25: 833‐839.
48. Martel G, Hamet P and Tremblay J [2010] Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome. Mol Cell Biochem 334: 53‐65.
49. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, Kishida K, Kihara S, Funahashi T and Shimomura I [2010] Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun 392: 100‐105.
50. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, Bouloumie A, Galitzky J, Arner P and Langin D [2007] Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50: 1038‐1047.
51. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM and Grant PJ [2011] Neprilysin, obesity and the metabolic syndrome. Int J Obes 35: 1031‐1040.
52. http://www.ncbi.nlm.nih.gov/books/NBK22251/ [1998] Obesity. Bethesda, MD: National Center for Biotechnology Information. Accessed January 19, 2011.
53. Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ, Park BH and Kim SH [2010] Leptin reduces plasma ANP level via nitric oxide‐dependent mechanism. Am J Physiol Regul Integr Comp Physiol 298: R1007‐R1016.
54. Beleigoli AM, Diniz MF and Ribiero AL [2009] Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions — A systematic review. Obes Rev 10: 617‐626.
55. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T and Nakao K [2009] Natriuretic peptides/cGMP/cGMP‐dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880‐2892.
56. Sengenes C, Stich V, Berlan M, Hejnova J, Lafontan M, Pariskova Z and Galitzky J [2002] Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low‐calorie diet in obese women. Int J Obes Relat Metab Disord 26: 24‐32.
57. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C and Galitzky J [2008] Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19: 130‐137.
58. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M, and Jordan J [2005] Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90: 3622‐3628.
59. Fischer JE and Bland KI [2007] Master of Surgery, volume 1. Fifth edition. Philadelphia: Lippincott Williams & Wilkins, p. 116.
60. Mtinangi BL and Hainsworth R [1998] Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Clin Auton Res 8: 231‐235.
61. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y and Kuriyama T [2005] Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea‐hypopnea syndrome. Chest 127: 716‐721.
62. Polotsky VY, Li J, Punjabi NM, Rubin AE, Smith PL, Schwartz AR and OʹDonnell CP [2003] Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 552(Part 1): 253‐264.
63. Qin L, Xiang Y, Song Z, Jing R, Hu C and Howard ST [2010] Erythropoetin as a possible mechanism for the effects of intermittent hypoxia on bodyweight, serum glucose and leptin in mice. Regul Pept 165: 168‐173.
64. Schulz R, Flötotto C, Jahn A, Eisele HJ, Weissmann N, Seeger W and Rose F [2006] Circulating adrenomedullin in obstructive sleep apnoea. J Sleep Res 15: 89‐95.
65. Chen YF [2005] Atrial natriuretic peptide in hypoxia. Peptides 26(6):1068‐77.
66. Kraiczi H, Magga J, Sun XY, Ruskoaho H, Zhao X and Hedner J [1999] Hypoxic pressor response, cardiac size, and natriuretic peptides are modified by long‐term intermittent hypoxia. J Appl Physiol 87: 2025‐2031.
67. Jiao J and Baertschi A [1993] Neural control of the endocrine rat heart. Proc Natl Acad Sci USA 90: 7799‐7803.
68. Sariman N, Levent E, Aksungar FB, Soylu AC and Bektas O [2010] Homocysteine levels and echocardiographic findings in obstructive sleep apnea syndrome. Respiration 79: 38‐45.
69. Gaillard CA, Koomans, HA and Mees EJ [1988] Enalapril attenuates natriuresis of atrial natriuretic factor in humans. Hypertension 11: 160‐165.
70. Ha YS, Tchey DU, Kang HW, Kim YJ, Yun SJ, Lee SC and Kim WJ [2010] Phosphaturia as a promising predictor of recurrent stone formation in patients with urolithiasis. Korean J Urol 51: 54‐59.
71. Sahebjani H [1998] Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 113: 1604‐1608.
72. Saito H, Nishimura M, Shibuya E, Makita H, Tsujino I, Miyamoto K and Kawakami Y [2002] Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. Chest 122: 1686‐1694.
73. Nadler JL and Rude RK [1995] Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 24: 623‐641.
74. Pall ML [2007] Explaining “Unexplained Illnesses” New York: The Haworth Press, Inc.
75. Nielsen FH [2010] Magnesium, inflammation, and obesity in chronic disease. Nutr Rev 68(6):333‐40.
76. Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B and Graham R [1999] An investigation of hypomagnesemia among ambulatory urban African Americans. J Fam Pract 48: 636‐639.
77. Fox CH, Mahoney MC, Ramsoomair D and Carter CA [2003] Magnesium deficiency in African‐Americans: Does it contribute to increased cardiovascular risk factors? J Nat Med Assoc 95: 257‐262.
78. Rayssiguier Y, Libako P, Nowacki W and Rock E [2010] Magnesium deficiency and metabolic syndrome: stress and inflammation may reflect calcium activation. Magnes Res 23: 73‐80.
79. Douban S, Brodsky MA, Whang DD and Whang R [1996] Significance of magnesium in congestive heart failure. Am Heart Journal 132: 664‐671.
80. Jones MD [2009] Deadly Sleep. New York: iUniverse Books.
81. McKie PM, Catalotti A, Huntley BK, Martin FL, Olson TM and Burnett JC Jr [2009] A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure‐lowering, renal‐enhancing, and aldosterone‐suppressing actions. J Am Coll Cardiol 54: 1024‐1032.
82. Resnick, LM, Barbagallo M, Bardicef M, Bardicef O, Sorokin Y, Evelhoch J, Dominguez LJ, Mason BA and Cotton DB [2004] Cellular‐free magnesium depletion in brain and muscle of normal and preeclamptic pregnancy: a nuclear magnetic resonance spectroscopic study. Hypertension 44: 322‐326.
83. Champagne KA, Kimoff RJ, Barriga PC and Schwartzman K [2010] Sleep disordered breathing in women of childbearing age & during pregnancy. Indian J Med Res 131: 285‐301.
84. Guilleminault C, Palombini L, Poyares D, Takaoka S, Huynh NT and El‐Sayed Y [2007] Pre‐eclampsia and nasal CPAP: part 1. Early intervention with nasal CPAP in pregnant women with risk factors for pre‐eclampsia: preliminary findings. Sleep Med 9: 9‐14.
85. Poyares D, Guilleminault C, Hachul H, Fujita L, Takaoka S, Tufik S and Sass N [2007] Pre‐eclampsia and nasal CPAP: Part 2. Hypertension during pregnancy, chronic snoring, and early nasal CPAP intervention. Sleep Med 9: 15‐21.
86. Spaanderman M, Ekhart, van Eyck J, de Leeuw P and Peeters L [2001] Preeclampsia and maladaptation to pregnancy: a role for atrial natriuretic peptide? Kidney Int 60: 1397‐1406.
87. Welch KMA [2003] Contemporary concepts of migraine pathogenesis. Neurology 61(8 Suppl. 4): S2‐S8.
88. Demirkaya S, Vural O, Dora B and Topcuoglu MA [2001] Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41: 171‐177.
89. Peikert A, Wilimzig C and Kohne‐Volland R [1996] Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo‐controlled and double‐blind randomized study. Cephalalgia 16: 257‐263.
90. Swaminathan R [2003] Magnesium metabolism and its disorders. Clin Biochem Rev 24: 47‐66.
91. González Bosc LV, Majowicz MP and Vidal NA [2000] Effects of atrial natriuretic peptide in the gut. Peptides 21: 875‐887.
92. Vesely DL, San Miguel GI, Hassan I, Gower WR Jr and Schocken DD [2001] Atrial natriuretic hormone, vessel dilator, long‐acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and free T4 and free T3 with reciprocal increase in TSH. J Clin Endocrinol Metab 86: 5438‐5442.
93. Everson CA and Reed HL [1995] Pituitary and peripheral thyroid hormone responses to thyrotropin‐releasing hormone during sustained sleep deprivation in freely moving rats. Endocrinology 136: 1426‐1434.
94. Everson C and Nowak TS Jr [2002] Hypothalamic thyrotropin‐releasing hormone mRNA responses to hypothyroxinemia induced by sleep deprivation. Am J Physiol Endocrinol Metab 283: E85‐E93.
95. Erden S, Cagatay T, Buyukozturk S, Kiyan E and Cuhadaroglu C [2004] Hashimoto thyroiditis and obstructive sleep apnea syndrome: is there any relation between them? Eur J Med Res 9: 570‐572.
96. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR and Burnett JC Jr [2002] Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40: 976‐982.
97. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M and Giannessi D [2002] The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 40: 371‐377.
98. Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ and de Lemos JA [2007] Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 49: 109‐116.
99. Battista MC, Oligny LL, St‐Louis J and Brochu M [2002] Intrauterine growth restriction in rats is associated with hypertension and renal dysfunction in adulthood. Am J Physiol Endocrinol Metab 283: E124‐E131.
100. Bridgeman P, Aronovitz MA, Kakkar R, Oliverio MI, Coffman TM, Rand WM, Konstam MA, Mendelsohn ME and Patten RD [2005] Gender‐specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. Am J Physiol Heart Circ Physiol 289: H586‐H592.
101. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohé C and Doevendans PA [2006] Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26: 1524‐1530.
102. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohé C, van Bilsen M and Doevendans PA [2004] 17β‐Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor‐cyclic guanosine monophosphate‐dependent protein kinase pathway. Circulation 109: 269‐276.
103. Deng Y and Kaufman S [1993] The influence of reproductive hormones on ANF release by rat atria. Life Sci 53: 689‐696.
104. Panayiotou CM, Baliga R, Stidwell R, Taylor V, Singer M and Hobbs AJ [2010] Resistance to endotoxic shock in mice lacking natriuretic peptide receptor‐A. Br J Pharmacol 160: 2045‐2054.
105. http://cgmp.blauplanet.com/path.html [2007] Dr. Luis Agullo December 28, 2007 Cyclic GMP Site, accessed June 13, 2011
106. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M and Rich TC [2006] Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128: 3‐14.
107. Kotlo KU, Rasenick MM and Danziger RS [2010] Evidence for cross‐talk between atrial natriuretic peptide and nitric oxide receptors. Mol Cell Biochem 338: 183‐189.
108. William M, Hamilton EJ, Garcia A, Bundgaard H, Chia KK, Figtree GA and Rasmussen HH [2008] Natriuretic peptides stimulate the cardiac sodium pump via NPR‐C‐coupled NOS activation. Am J Physiol Cell Physiol 294: C1067‐C1073.
109. Elesgaray R, Caniffi C, Ierace DR, Jaime MF, Fellet A, Arranz C and Costa MA [2008] Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide. Regul Pept 151: 130‐134.
110. Costa MA, Elesgaray R, Caniffi C, Fellet A, MacLaughlin M and Arranz C [2010] Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic peptide in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 298: H778‐H786
111. Nakayama R, Harada N, Asano M, Nomura N, Saito T, Mishima A and Okajima K [2007] Atrial natriuretic peptide reduces ischemia/reperfusion‐induced spinal cord injury in rats by enhancing sensory neuron activation. J Pharmacol Exp Ther 322: 582‐590.
112. Eftekhari S and Edvinsson L [2010] Possible sites of action of the new calcitonin gene‐related peptide receptor antagonists. Ther Adv Neurol Disord 3: 369‐378.
113. Wiggins AK, Shen PJ and Gundlach AL [2003] Atrial natriuretic peptide expression is increased in rat cerebral cortex following spreading depression: possible contribution to sd‐induced neuroprotection. Neuroscience 118: 715‐726.
114. Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F and Maione S [2010] Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol Pain 6: 66.
115. Church DJ, Arkinstall SJ, Vallotton MB, Chollet A, Kawashima E and Lang U [1996] Stimulation of atrial natriuretic peptide release by neurokinins in neonatal rat ventricular cardiomyocytes. Am J Physiol 270(3 Part 2): H935‐H944.
116. Piao FL, Cao C, Han JH, Kim SZ and Kim SH [2004] Calcitonin gene‐related peptide‐induced suppression of atrial natriuretic peptide release through receptors for CGRP1 but not for calcitonin and amylin. Eur J Pharmacol 483: 295‐300.
117. Schiebinger RJ and Santora AC [1989] Stimulation by calcitonin gene‐related peptide of atrial natriuretic peptide secretion in vitro and its mechanism of action. Endocrinology 124: 2473‐2479.
118. Yamamoto A, Kimura S, Hasui K, Fujisawa Y, Tamaki T, Fukui K, Iwao H and Abe Y [1988] Calcitonin gene‐related peptide (CGRP) stimulates the release of atrial natriuretic peptide (ANP) from isolated rat atria. Biochem Biophys Res Commun 155: 1452‐1458.
119. Cortright DN and Szallasi A [2004] Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 271: 1814‐1819.
120. Lin Q, Li D, Xu X, Zou X and Fang L [2007] Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex‐mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain 3: 30.
121. Kuribayashi K, Kitaoka Y, Kumai T, Munemasa Y, Kitaoka Y, Isenoumi K, Motoki M, Kogo J, Hayashi Y, Kobayashi S and Ueno S [2006] Neuroprotective effect of atrial natriuretic peptide against NMDA‐induced neurotoxicity in the rat retina. Brain Res 1071: 34‐41.
122. Kovács GL [2000] Atrial natriuretic peptide modulates N‐methyl‐D‐aspartate‐induced hyperexcitability in ethanol‐dependent mice. Eur J Pharmacol 401: 343‐347.
123. Bjelland I, Tell GS, Vollset SE, Refsum H and Ueland PM [2003] Folate, vitamin B12, homocysteine, and the MTHFR 677C‐>T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 60: 618‐626.
124. De Vito P, Incerpi S, Pedersen JZ and Luly P [2010] Atrial natriuretic peptide and oxidative stress. Peptides 31: 1412‐1419.
125. Scarpino S, Marchitti S, Stanzione R, Evangelista A, Di Castro S, Savoia C, Quarta G, Sciarretta S, Ruco L, Volpe M, and Rubattu S [2009] Reactive oxygen species‐mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J Hypertens 27: 1804‐1813.
126. Nannipieri M, Manganiello M, Pezzatini A, De Bellis A, Seghieri G and Ferrannini E [2001] Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension. Hypertension 37: 1416‐1422.
127. Koga H, Hagiwara S, Shingu C, Matsumoto S, Yokoi I and Noguchi T [2010] Human atrial natriuretic peptide ameliorates LPS‐induced acute lung injury in rats. Lung 188: 241‐246.
128. Vellaichamy E, Kaur K and Pandey KN [2007] Enhanced activation of pro‐inflammatory cytokines in mice lacking natriuretic peptide receptor‐A. Peptides 28: 893‐899.
129. Ladetzki‐Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A and Vollmar AM [2007] Atrial natriuretic peptide, a regulator of nuclear factor‐kappaB activation in vivo. Endocrinology 148: 332‐336.
130. Kiemer AK, Weber NC and Vollmar AM [2002] Induction of IkappaB: atrial natriuretic peptide as a regulator of the NF‐kappaB pathway. Biochem Biophys Res Commun 295: 1068‐1076.
131. Baldwin CM, Kapur VK, Holberg CJ, Rosen C, Nieto FJ and Sleep Heart Health Study Group [2004] Associations between gender and measures of daytime somnolence in the Sleep Heart Health Study. Sleep 27: 305‐311.
132. Krakow B [2007] Sound Sleep, Sound Mind. Hoboken, NJ: John Wiley and Sons, Inc.
133. Yuan K, Kim SY, Oh YB, Yu J, Shah A, Park BH and Kim SH [2010] Upregulation of ANP and NPR‐C mRNA in the kidney and heart of eNOS knockout mice. Peptides 31: 1319‐1325.
134. Dickey DM, Yoder AR and Potter LR [2009] A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 284(29):19196‐202.
135. Yasko A [2005] Genetic ByPass. Matrix Development Publishing.
136. Blaise S, Alberto JM, Nédélec E, Ayav A, Pourié G, Bronowicki JP, Guéant JL and Daval JL [2005] Mild neonatal hypoxia exacerbates the effects of vitamin‐deficient diet on homocysteine metabolism in rats. Pediatr Res 57: 777‐782.
137. Levine J, Timinsky I, Vishne T, Dwolatzky T, Roitman S, Kaplan Z, Kotler M, Sela BA and Spivak B [2008] Elevated serum homocysteine levels in male patients with PTSD. Depress Anxiety 25: E154‐E157.
138. Wang L, Li J, Xie Y and Zhang XG [2010] Association between serum homocysteine and oxidative stress in elderly patients with obstructive sleep apnea/hypopnea syndrome. Biomed Environ Sci 23: 42‐47.
139. Jendricko T, Vidović A, Grubisić‐Ilić M, Romić Z, Kovacić Z and Kozarić‐Kovacić D [2009] Homocysteine and seum lipids concentration in male war veterans with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 33: 134‐140.
140. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, DʹAgostino RB, Wilson PW and Wolf PA [2002] Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346(7):476‐83.
141. Scholl TO and Johnson WG [2000] Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 71(5 Suppl): 1295S‐1303S.
142. James SJ, Melnyk S, Jernigan S, Pavliv O, Trusty T, Lehman S, Seidel L, Gaylor DW and Cleves MA [2010] A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. Am J Med Genet B Neuropsychiatr Genet 153B: 1209‐1220.
143. Mann JR, McDermott S, Bao H, Hardin J and Gregg A [2010] Pre‐eclampsia, birth weight, and autism spectrum disorders. J Autism Dev Disord 40: 548‐554.
144. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW and Neubrander JA [2004] Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80: 1611‐1617.
145. Adams M, Lucock M, Stuart J, Fardell S, Baker K and Ng X [2007] Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion‐DHFR in occurence of autism. Neurosci Lett 422: 24‐29.
146. Bidzseranova A, Gueron J, Penk B and Telegdy G [1991] The effects of atrial natriuretic peptide on active avoidance behavior in rats. The role of neurotransmitters. Pharmacol Biochem Behav 40: 61‐64.
147. Chila A, Fitzgerald M [2011] Foundations of Osteopathic Medicine, American Osteopathic Association. Philadelphia: Lippincott, Williams and Wilkins.
148. Liu PY, Yee B, Wishart SM, Jimenez M, Jung DG, Grunstein RR and Handelsman DJ [2003] The short‐term effects of high‐dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 88: 3605‐3613.
149. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A and White DP [2001] Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86: 1175‐1180.
Conflict of interest statement: The author has no conflict of interest to declare.
1. Guilleminault C and De Los Reyes V [2011] Upper‐airway resistance syndrome. Handbook of Clinical Neurology 98: 401‐409.
2. Newman JP, Clerk AA, Moore M, Utley DS and Terris DJ [1996] Recognition and surgical management of the upper airway resistance syndrome. Laryngoscope 106 (9 Pt 1): 1089‐1093.
3. Lin CH and Guilleminault C [2011] Current hypopnea scoring criteria underscore pediatric sleep disordered breathing. Sleep Medicine 12: 720‐729.
4. Ruehland WR, Rochford PD, O’Donoghue FJ, Pierce RJ, Singh P and Thornton AT [2009] The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index. Sleep 32: 150‐157.
5. Gold AR, Dipalo F, Gold MS and O’Hearn D [2003] The symptoms and signs of upper airway resistance syndrome: a link to the functional somatic syndromes. Chest 123: 87‐95.
6. Guilleminault C, Kirisoglu C, Poyares D, Palombini L, Leger D, Farid‐Moayer M and Ohayon MM [2006] Upper Airway Resistance Syndrome: a long‐term outcome study. J Psychiatr Res 40: 273‐279.
7. Park SY [2008] Sleep Interrupted. New York: Jodev Press, LLC.
8. Haba‐Rubio J, Andries D, Bastardot F, Tobback N, Vollenweider P, Tafti M and Heinzer R [2011] Prevalence of sleep disordered breathing in middle‐aged general population: the Hypnolaus study. Sleep 34: A123
9. Tufik S, Santos‐Silva R, Taddei JA and Azeredo Bittencourt LR [2010] Obstructive sleep apnea syndrome in the Sao Paolo epidemiologic sleep study. Sleep Medicine 11: 441‐446.
10. Umlauf MG and Chasens ER [2003] Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med Rev 7: 403‐411.
11. Kalra PR and Tigas S [2002] Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125‐132.
12. Potter LF, Yoder AR, Flora DR, Antos LK and Dickey DM [2009] Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191: 341‐366.
13. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA and Livesey JH [1986] Metabolic clearance rate and plasma half life of alpha‐human atrial natriuretic peptide in man. Life Sci 38: 1827‐1833.
14. Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H, Uemura S and Saito Y [2007] ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 63: 699‐702.
15. Ikeda N, Yasu T, Nishikimi T, Nakamura T, Kubo N, Kawakami M, Momomura S and Saito M [2007] N‐terminal pro‐atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. Regul Pept 141(1‐3): 154‐158.
16. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T and Burnett JC Jr [2010] A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension 56: 1152‐1159.
17. Imaizumi T and Takeshita A [1993] Influence of ANP on sympathetic nerve activity and chronotropic regulation of the heart. J Cardiovasc Electrophysiol 4: 719‐729.
18. Porzionato A, Macchi V, Rucinski M, Malendowicz LK and De Caro R [2010] Natriuretic peptides in the regulation of the hypothalamic‐pituitary‐adrenal axis. Int Rev Cell Mol Biol 280: 1‐39.
19. Chartier L, Schiffrin E and Thibault G [1984] Effect of atrial natriuretic factor (ANF)‐related peptides on aldosterone secretion by adrenal glomerulosa cells: critical role of the intramolecular disulphide bond. Biochem Biophys Res Commun 122: 171‐174.
20. Atlas SA, Volpe M, Sosa RE, Laragh JH, Camargo MJ and Maack T [1986] Effects of atrial natriuretic factor on blood pressure and the renin‐angiotensin‐aldosterone system. Fed Proc 45: 2115‐2121.
21. Pizzorno JE and Murray MT [1999] Textbook of Natural Medicine, second edition. Edinburgh: Harcourt Publishers Limited.
22. Demitrack MA, Dale JK and Straus SE [1991] Evidence for impaired activation of the hypothalamic‐pituitary‐adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 73: 1224‐1234.
23. Demiralay C, Jahn H, Kellner M, Yassouridis A and Weidemann K [2010] Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic‐pituitary‐adrenal axis and sleep in healthy men. Psychoneuroendocrinology 35: 1438‐1445.
24. Perras B, Schultes B, Behn B, Dodt C, Born J and Fehm HL [2004] Intranasal atrial natriuretic peptide acts as central nervous inhibitor of the hypothalamic‐pituitary‐adrenal stress system in humans. J Clin Endocrinol Metab 89: 4642‐4648.
25. Boneva RS, Decker MJ, Maloney EM, Lin JM, Jones JF, Helgason HG, Heim CM, Rye DB and Reeves WC [2007] Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population based study. Auton Neurosci 137: 94‐101.
26. Anderberg UM and Uvnas‐Moberg K [2000] Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 59: 373‐379.
27. Wyller VB, Evang JA, Godang K, Solhjell KK and Bollerslev J [2010] Hormonal alterations in adolescent chronic fatigue syndrome. Acta Paediatr 99: 770‐773.
28. Krakow B, Melendrez D, Warner TD, Dorin R, Harper R and Hollifield M [2002] To breathe, perchance to sleep: sleep‐disordered breathing and chronic insomnia among trauma survivors. Sleep Breath 6: 189‐202.
29. Gold AR [2011] Functional somatic syndromes, anxiety disorders and the upper airway: A matter of paradigms. Sleep Med Rev 15: 389‐401.
30. Amin MM, Belisova Z, Hossain S, Gold MS, Broderick JE and Gold AR [2011] Inspiratory airflow dynamics during sleep in veterans with Gulf War illness: a controlled study. Sleep Breath 15: 333‐339.
31. Freund BJ, Wade CE and Claybaugh J [1988] Effects of exercise on atrial natriuretic factor. Release mechanisms and implications for fluid homeostasis. Sports Med 6: 364‐377.
32. Kita H, Ohi M, Chin K, Noguchi T, Otsuka N, Tsuboi T, Itoh H, Nakao K and Kuno K [1998] The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 7: 199‐207.
33. Schafer H, Ehlenz K, Ewig S, Hasper E, Koehler U, Latzelsberger J, Tasci S and Luderitz B [1999] Atrial natriuretic peptide levels and pulmonary artery pressure awake, at exercise and asleep in obstructive sleep apnoea syndrome. J Sleep Res 8: 205‐210.
34. Svatikova A, Shamsuzzaman, AS, Wolk R, Phillips BG, Olson LJ and Somers VK [2004] Plasma brain natriuretic peptide in obstructive sleep apnea. Am J Cardiol 94: 529‐532.
35. Lin CC, Tsan KW and Lin CY [1993] Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep 16: 37‐39.
36. Ichioka M, Hirata Y, Inase N, Tojo N, Yoshizawa M, Chida M, Miyazato I, Taniai S and Marumo F [1992] Changes of circulating atrial natriuretic peptide and antidiuretic hormone in obstructive sleep apnea syndrome. Respiration 59: 164‐168.
37. Patwardhan AA, Larson MG, Levy D, Benjamin EF, Leip EP, Keyes MJ, Wang TJ, Gottlieb DJ and Vasan RS [2006] Obstructive sleep apnea and plasma natriuretic peptide levels in a community‐based sample. Sleep 29: 1301‐1306.
38. Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V and Poulin MJ [2010] Intermittent hypoxia increases arterial blood pressure in humans through a Renin‐Angiotensin system‐dependent mechanism. Hypertension 56: 369‐377.
39. Møller DS, Lind P, Strunge B and Pedersen EB [2003] Abnormal vasoactive hormones and 24‐hour blood pressure in obstructive sleep apnea. Am J Hypertens 16: 274‐280.
40. Matsukawa T and Miyamoto T [2011] Angiotensin II‐stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol 300: R624‐R629.
41. Oh YB, Gao S, Shah A, Kim JH, Park WH and Kim SH [2011] Endogenous angiotensin II suppresses stretch‐induced ANP secretion via AT1 receptor pathway. Peptides 32: 374‐381.
42. Dietz JR [2005] Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 66: 8‐17.
43. De Pergola G, Garruti G, Giorgino F, Cospite MR, Corso M, Cignarelli M and Giorgino R [1994] Reduced effectiveness of atrial natriuretic factor in pre‐menopausal obese women. Int J Obes Relat Metab Disord 18: 93‐97.
44. Beltowski J, Jamroz‐Wisniewka A, Borkowska E and Marciniak A [2006] Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic peptide associated with obesity and hyperleptinemia 37: 307‐315.
45. Schiffrin EL and St‐Louis J [1987] Decreased density of vascular receptors for atrial natriuretic peptide in DOCA‐salt hypertensive rats. Hypertension 9: 504‐512.
46. Licata G, Volpe M, Scaglione R and Rubattu S [1994] Salt‐regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23(1 Suppl): 120‐124.
47. Rubattu, S, Sciarretta S, Ciavarella GM, Venturelli V, De Paolis P, Tocci G, De Biase L, Ferrucci A and Volpe M [2007] Reduced levels of N‐terminal‐proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertens 25: 833‐839.
48. Martel G, Hamet P and Tremblay J [2010] Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome. Mol Cell Biochem 334: 53‐65.
49. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, Kishida K, Kihara S, Funahashi T and Shimomura I [2010] Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun 392: 100‐105.
50. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, Bouloumie A, Galitzky J, Arner P and Langin D [2007] Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50: 1038‐1047.
51. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM and Grant PJ [2011] Neprilysin, obesity and the metabolic syndrome. Int J Obes 35: 1031‐1040.
52. http://www.ncbi.nlm.nih.gov/books/NBK22251/ [1998] Obesity. Bethesda, MD: National Center for Biotechnology Information. Accessed January 19, 2011.
53. Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ, Park BH and Kim SH [2010] Leptin reduces plasma ANP level via nitric oxide‐dependent mechanism. Am J Physiol Regul Integr Comp Physiol 298: R1007‐R1016.
54. Beleigoli AM, Diniz MF and Ribiero AL [2009] Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions — A systematic review. Obes Rev 10: 617‐626.
55. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T and Nakao K [2009] Natriuretic peptides/cGMP/cGMP‐dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880‐2892.
56. Sengenes C, Stich V, Berlan M, Hejnova J, Lafontan M, Pariskova Z and Galitzky J [2002] Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low‐calorie diet in obese women. Int J Obes Relat Metab Disord 26: 24‐32.
57. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C and Galitzky J [2008] Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19: 130‐137.
58. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M, and Jordan J [2005] Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90: 3622‐3628.
59. Fischer JE and Bland KI [2007] Master of Surgery, volume 1. Fifth edition. Philadelphia: Lippincott Williams & Wilkins, p. 116.
60. Mtinangi BL and Hainsworth R [1998] Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Clin Auton Res 8: 231‐235.
61. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y and Kuriyama T [2005] Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea‐hypopnea syndrome. Chest 127: 716‐721.
62. Polotsky VY, Li J, Punjabi NM, Rubin AE, Smith PL, Schwartz AR and OʹDonnell CP [2003] Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 552(Part 1): 253‐264.
63. Qin L, Xiang Y, Song Z, Jing R, Hu C and Howard ST [2010] Erythropoetin as a possible mechanism for the effects of intermittent hypoxia on bodyweight, serum glucose and leptin in mice. Regul Pept 165: 168‐173.
64. Schulz R, Flötotto C, Jahn A, Eisele HJ, Weissmann N, Seeger W and Rose F [2006] Circulating adrenomedullin in obstructive sleep apnoea. J Sleep Res 15: 89‐95.
65. Chen YF [2005] Atrial natriuretic peptide in hypoxia. Peptides 26(6):1068‐77.
66. Kraiczi H, Magga J, Sun XY, Ruskoaho H, Zhao X and Hedner J [1999] Hypoxic pressor response, cardiac size, and natriuretic peptides are modified by long‐term intermittent hypoxia. J Appl Physiol 87: 2025‐2031.
67. Jiao J and Baertschi A [1993] Neural control of the endocrine rat heart. Proc Natl Acad Sci USA 90: 7799‐7803.
68. Sariman N, Levent E, Aksungar FB, Soylu AC and Bektas O [2010] Homocysteine levels and echocardiographic findings in obstructive sleep apnea syndrome. Respiration 79: 38‐45.
69. Gaillard CA, Koomans, HA and Mees EJ [1988] Enalapril attenuates natriuresis of atrial natriuretic factor in humans. Hypertension 11: 160‐165.
70. Ha YS, Tchey DU, Kang HW, Kim YJ, Yun SJ, Lee SC and Kim WJ [2010] Phosphaturia as a promising predictor of recurrent stone formation in patients with urolithiasis. Korean J Urol 51: 54‐59.
71. Sahebjani H [1998] Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 113: 1604‐1608.
72. Saito H, Nishimura M, Shibuya E, Makita H, Tsujino I, Miyamoto K and Kawakami Y [2002] Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. Chest 122: 1686‐1694.
73. Nadler JL and Rude RK [1995] Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 24: 623‐641.
74. Pall ML [2007] Explaining “Unexplained Illnesses” New York: The Haworth Press, Inc.
75. Nielsen FH [2010] Magnesium, inflammation, and obesity in chronic disease. Nutr Rev 68(6):333‐40.
76. Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B and Graham R [1999] An investigation of hypomagnesemia among ambulatory urban African Americans. J Fam Pract 48: 636‐639.
77. Fox CH, Mahoney MC, Ramsoomair D and Carter CA [2003] Magnesium deficiency in African‐Americans: Does it contribute to increased cardiovascular risk factors? J Nat Med Assoc 95: 257‐262.
78. Rayssiguier Y, Libako P, Nowacki W and Rock E [2010] Magnesium deficiency and metabolic syndrome: stress and inflammation may reflect calcium activation. Magnes Res 23: 73‐80.
79. Douban S, Brodsky MA, Whang DD and Whang R [1996] Significance of magnesium in congestive heart failure. Am Heart Journal 132: 664‐671.
80. Jones MD [2009] Deadly Sleep. New York: iUniverse Books.
81. McKie PM, Catalotti A, Huntley BK, Martin FL, Olson TM and Burnett JC Jr [2009] A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure‐lowering, renal‐enhancing, and aldosterone‐suppressing actions. J Am Coll Cardiol 54: 1024‐1032.
82. Resnick, LM, Barbagallo M, Bardicef M, Bardicef O, Sorokin Y, Evelhoch J, Dominguez LJ, Mason BA and Cotton DB [2004] Cellular‐free magnesium depletion in brain and muscle of normal and preeclamptic pregnancy: a nuclear magnetic resonance spectroscopic study. Hypertension 44: 322‐326.
83. Champagne KA, Kimoff RJ, Barriga PC and Schwartzman K [2010] Sleep disordered breathing in women of childbearing age & during pregnancy. Indian J Med Res 131: 285‐301.
84. Guilleminault C, Palombini L, Poyares D, Takaoka S, Huynh NT and El‐Sayed Y [2007] Pre‐eclampsia and nasal CPAP: part 1. Early intervention with nasal CPAP in pregnant women with risk factors for pre‐eclampsia: preliminary findings. Sleep Med 9: 9‐14.
85. Poyares D, Guilleminault C, Hachul H, Fujita L, Takaoka S, Tufik S and Sass N [2007] Pre‐eclampsia and nasal CPAP: Part 2. Hypertension during pregnancy, chronic snoring, and early nasal CPAP intervention. Sleep Med 9: 15‐21.
86. Spaanderman M, Ekhart, van Eyck J, de Leeuw P and Peeters L [2001] Preeclampsia and maladaptation to pregnancy: a role for atrial natriuretic peptide? Kidney Int 60: 1397‐1406.
87. Welch KMA [2003] Contemporary concepts of migraine pathogenesis. Neurology 61(8 Suppl. 4): S2‐S8.
88. Demirkaya S, Vural O, Dora B and Topcuoglu MA [2001] Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41: 171‐177.
89. Peikert A, Wilimzig C and Kohne‐Volland R [1996] Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo‐controlled and double‐blind randomized study. Cephalalgia 16: 257‐263.
90. Swaminathan R [2003] Magnesium metabolism and its disorders. Clin Biochem Rev 24: 47‐66.
91. González Bosc LV, Majowicz MP and Vidal NA [2000] Effects of atrial natriuretic peptide in the gut. Peptides 21: 875‐887.
92. Vesely DL, San Miguel GI, Hassan I, Gower WR Jr and Schocken DD [2001] Atrial natriuretic hormone, vessel dilator, long‐acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and free T4 and free T3 with reciprocal increase in TSH. J Clin Endocrinol Metab 86: 5438‐5442.
93. Everson CA and Reed HL [1995] Pituitary and peripheral thyroid hormone responses to thyrotropin‐releasing hormone during sustained sleep deprivation in freely moving rats. Endocrinology 136: 1426‐1434.
94. Everson C and Nowak TS Jr [2002] Hypothalamic thyrotropin‐releasing hormone mRNA responses to hypothyroxinemia induced by sleep deprivation. Am J Physiol Endocrinol Metab 283: E85‐E93.
95. Erden S, Cagatay T, Buyukozturk S, Kiyan E and Cuhadaroglu C [2004] Hashimoto thyroiditis and obstructive sleep apnea syndrome: is there any relation between them? Eur J Med Res 9: 570‐572.
96. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR and Burnett JC Jr [2002] Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40: 976‐982.
97. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M and Giannessi D [2002] The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 40: 371‐377.
98. Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ and de Lemos JA [2007] Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 49: 109‐116.
99. Battista MC, Oligny LL, St‐Louis J and Brochu M [2002] Intrauterine growth restriction in rats is associated with hypertension and renal dysfunction in adulthood. Am J Physiol Endocrinol Metab 283: E124‐E131.
100. Bridgeman P, Aronovitz MA, Kakkar R, Oliverio MI, Coffman TM, Rand WM, Konstam MA, Mendelsohn ME and Patten RD [2005] Gender‐specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. Am J Physiol Heart Circ Physiol 289: H586‐H592.
101. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohé C and Doevendans PA [2006] Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26: 1524‐1530.
102. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohé C, van Bilsen M and Doevendans PA [2004] 17β‐Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor‐cyclic guanosine monophosphate‐dependent protein kinase pathway. Circulation 109: 269‐276.
103. Deng Y and Kaufman S [1993] The influence of reproductive hormones on ANF release by rat atria. Life Sci 53: 689‐696.
104. Panayiotou CM, Baliga R, Stidwell R, Taylor V, Singer M and Hobbs AJ [2010] Resistance to endotoxic shock in mice lacking natriuretic peptide receptor‐A. Br J Pharmacol 160: 2045‐2054.
105. http://cgmp.blauplanet.com/path.html [2007] Dr. Luis Agullo December 28, 2007 Cyclic GMP Site, accessed June 13, 2011
106. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M and Rich TC [2006] Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128: 3‐14.
107. Kotlo KU, Rasenick MM and Danziger RS [2010] Evidence for cross‐talk between atrial natriuretic peptide and nitric oxide receptors. Mol Cell Biochem 338: 183‐189.
108. William M, Hamilton EJ, Garcia A, Bundgaard H, Chia KK, Figtree GA and Rasmussen HH [2008] Natriuretic peptides stimulate the cardiac sodium pump via NPR‐C‐coupled NOS activation. Am J Physiol Cell Physiol 294: C1067‐C1073.
109. Elesgaray R, Caniffi C, Ierace DR, Jaime MF, Fellet A, Arranz C and Costa MA [2008] Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide. Regul Pept 151: 130‐134.
110. Costa MA, Elesgaray R, Caniffi C, Fellet A, MacLaughlin M and Arranz C [2010] Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic peptide in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 298: H778‐H786
111. Nakayama R, Harada N, Asano M, Nomura N, Saito T, Mishima A and Okajima K [2007] Atrial natriuretic peptide reduces ischemia/reperfusion‐induced spinal cord injury in rats by enhancing sensory neuron activation. J Pharmacol Exp Ther 322: 582‐590.
112. Eftekhari S and Edvinsson L [2010] Possible sites of action of the new calcitonin gene‐related peptide receptor antagonists. Ther Adv Neurol Disord 3: 369‐378.
113. Wiggins AK, Shen PJ and Gundlach AL [2003] Atrial natriuretic peptide expression is increased in rat cerebral cortex following spreading depression: possible contribution to sd‐induced neuroprotection. Neuroscience 118: 715‐726.
114. Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F and Maione S [2010] Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol Pain 6: 66.
115. Church DJ, Arkinstall SJ, Vallotton MB, Chollet A, Kawashima E and Lang U [1996] Stimulation of atrial natriuretic peptide release by neurokinins in neonatal rat ventricular cardiomyocytes. Am J Physiol 270(3 Part 2): H935‐H944.
116. Piao FL, Cao C, Han JH, Kim SZ and Kim SH [2004] Calcitonin gene‐related peptide‐induced suppression of atrial natriuretic peptide release through receptors for CGRP1 but not for calcitonin and amylin. Eur J Pharmacol 483: 295‐300.
117. Schiebinger RJ and Santora AC [1989] Stimulation by calcitonin gene‐related peptide of atrial natriuretic peptide secretion in vitro and its mechanism of action. Endocrinology 124: 2473‐2479.
118. Yamamoto A, Kimura S, Hasui K, Fujisawa Y, Tamaki T, Fukui K, Iwao H and Abe Y [1988] Calcitonin gene‐related peptide (CGRP) stimulates the release of atrial natriuretic peptide (ANP) from isolated rat atria. Biochem Biophys Res Commun 155: 1452‐1458.
119. Cortright DN and Szallasi A [2004] Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 271: 1814‐1819.
120. Lin Q, Li D, Xu X, Zou X and Fang L [2007] Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex‐mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain 3: 30.
121. Kuribayashi K, Kitaoka Y, Kumai T, Munemasa Y, Kitaoka Y, Isenoumi K, Motoki M, Kogo J, Hayashi Y, Kobayashi S and Ueno S [2006] Neuroprotective effect of atrial natriuretic peptide against NMDA‐induced neurotoxicity in the rat retina. Brain Res 1071: 34‐41.
122. Kovács GL [2000] Atrial natriuretic peptide modulates N‐methyl‐D‐aspartate‐induced hyperexcitability in ethanol‐dependent mice. Eur J Pharmacol 401: 343‐347.
123. Bjelland I, Tell GS, Vollset SE, Refsum H and Ueland PM [2003] Folate, vitamin B12, homocysteine, and the MTHFR 677C‐>T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 60: 618‐626.
124. De Vito P, Incerpi S, Pedersen JZ and Luly P [2010] Atrial natriuretic peptide and oxidative stress. Peptides 31: 1412‐1419.
125. Scarpino S, Marchitti S, Stanzione R, Evangelista A, Di Castro S, Savoia C, Quarta G, Sciarretta S, Ruco L, Volpe M, and Rubattu S [2009] Reactive oxygen species‐mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J Hypertens 27: 1804‐1813.
126. Nannipieri M, Manganiello M, Pezzatini A, De Bellis A, Seghieri G and Ferrannini E [2001] Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension. Hypertension 37: 1416‐1422.
127. Koga H, Hagiwara S, Shingu C, Matsumoto S, Yokoi I and Noguchi T [2010] Human atrial natriuretic peptide ameliorates LPS‐induced acute lung injury in rats. Lung 188: 241‐246.
128. Vellaichamy E, Kaur K and Pandey KN [2007] Enhanced activation of pro‐inflammatory cytokines in mice lacking natriuretic peptide receptor‐A. Peptides 28: 893‐899.
129. Ladetzki‐Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A and Vollmar AM [2007] Atrial natriuretic peptide, a regulator of nuclear factor‐kappaB activation in vivo. Endocrinology 148: 332‐336.
130. Kiemer AK, Weber NC and Vollmar AM [2002] Induction of IkappaB: atrial natriuretic peptide as a regulator of the NF‐kappaB pathway. Biochem Biophys Res Commun 295: 1068‐1076.
131. Baldwin CM, Kapur VK, Holberg CJ, Rosen C, Nieto FJ and Sleep Heart Health Study Group [2004] Associations between gender and measures of daytime somnolence in the Sleep Heart Health Study. Sleep 27: 305‐311.
132. Krakow B [2007] Sound Sleep, Sound Mind. Hoboken, NJ: John Wiley and Sons, Inc.
133. Yuan K, Kim SY, Oh YB, Yu J, Shah A, Park BH and Kim SH [2010] Upregulation of ANP and NPR‐C mRNA in the kidney and heart of eNOS knockout mice. Peptides 31: 1319‐1325.
134. Dickey DM, Yoder AR and Potter LR [2009] A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 284(29):19196‐202.
135. Yasko A [2005] Genetic ByPass. Matrix Development Publishing.
136. Blaise S, Alberto JM, Nédélec E, Ayav A, Pourié G, Bronowicki JP, Guéant JL and Daval JL [2005] Mild neonatal hypoxia exacerbates the effects of vitamin‐deficient diet on homocysteine metabolism in rats. Pediatr Res 57: 777‐782.
137. Levine J, Timinsky I, Vishne T, Dwolatzky T, Roitman S, Kaplan Z, Kotler M, Sela BA and Spivak B [2008] Elevated serum homocysteine levels in male patients with PTSD. Depress Anxiety 25: E154‐E157.
138. Wang L, Li J, Xie Y and Zhang XG [2010] Association between serum homocysteine and oxidative stress in elderly patients with obstructive sleep apnea/hypopnea syndrome. Biomed Environ Sci 23: 42‐47.
139. Jendricko T, Vidović A, Grubisić‐Ilić M, Romić Z, Kovacić Z and Kozarić‐Kovacić D [2009] Homocysteine and seum lipids concentration in male war veterans with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 33: 134‐140.
140. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, DʹAgostino RB, Wilson PW and Wolf PA [2002] Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346(7):476‐83.
141. Scholl TO and Johnson WG [2000] Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 71(5 Suppl): 1295S‐1303S.
142. James SJ, Melnyk S, Jernigan S, Pavliv O, Trusty T, Lehman S, Seidel L, Gaylor DW and Cleves MA [2010] A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. Am J Med Genet B Neuropsychiatr Genet 153B: 1209‐1220.
143. Mann JR, McDermott S, Bao H, Hardin J and Gregg A [2010] Pre‐eclampsia, birth weight, and autism spectrum disorders. J Autism Dev Disord 40: 548‐554.
144. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW and Neubrander JA [2004] Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80: 1611‐1617.
145. Adams M, Lucock M, Stuart J, Fardell S, Baker K and Ng X [2007] Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion‐DHFR in occurence of autism. Neurosci Lett 422: 24‐29.
146. Bidzseranova A, Gueron J, Penk B and Telegdy G [1991] The effects of atrial natriuretic peptide on active avoidance behavior in rats. The role of neurotransmitters. Pharmacol Biochem Behav 40: 61‐64.
147. Chila A, Fitzgerald M [2011] Foundations of Osteopathic Medicine, American Osteopathic Association. Philadelphia: Lippincott, Williams and Wilkins.
148. Liu PY, Yee B, Wishart SM, Jimenez M, Jung DG, Grunstein RR and Handelsman DJ [2003] The short‐term effects of high‐dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 88: 3605‐3613.
149. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A and White DP [2001] Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86: 1175‐1180.
Conflict of interest statement: The author has no conflict of interest to declare.